BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26792387)

  • 1. PARP inhibition in castration-resistant prostate cancer.
    Nappi L; Gleave ME
    Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
    [No Abstract]   [Full Text] [Related]  

  • 2. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratifying prostate patients for olaparib.
    Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
    [No Abstract]   [Full Text] [Related]  

  • 7. PARP inhibitors in castration-resistant prostate cancer.
    Tripathi A; Balakrishna P; Agarwal N
    Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibitors for homologous recombination-deficient prostate cancer.
    Christenson ES; Antonarakis ES
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):123-133. PubMed ID: 29595348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibition in BRCA2-mutated prostate cancer.
    Nientiedt C; Tolstov Y; Volckmar AL; Endris V; Bonekamp D; Haberkorn U; Jäger D; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
    Ann Oncol; 2017 Jan; 28(1):189-191. PubMed ID: 27687312
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
    BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer.
    Mouw KW; Choudhury AD
    Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    Castro E; Mateo J; Olmos D; de Bono JS
    Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    Saillant A; Flippot R
    Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
    [No Abstract]   [Full Text] [Related]  

  • 14. PARP inhibitors for prostate cancer.
    Longoria O; Beije N; de Bono JS
    Semin Oncol; 2024; 51(1-2):25-35. PubMed ID: 37783649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
    Beije N; Abida W; Antonarakis ES; Castro E; de Wit R; Fizazi K; Gillessen S; Hussain M; Mateo J; Morris MJ; Olmos D; Sartor O; Sharp A; Sweeney CJ; de Bono JS
    Eur Urol; 2023 Sep; 84(3):253-256. PubMed ID: 37087376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP Inhibitors in Prostate Cancer.
    Ramakrishnan Geethakumari P; Schiewer MJ; Knudsen KE; Kelly WK
    Curr Treat Options Oncol; 2017 Jun; 18(6):37. PubMed ID: 28540598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of PARP inhibitors in prostate cancer.
    Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
    Helleday T
    Ann Oncol; 2016 May; 27(5):755-7. PubMed ID: 26865580
    [No Abstract]   [Full Text] [Related]  

  • 19. Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer.
    Akbıyık I; Ürün Y
    Future Oncol; 2023 Dec; 19(39):2585-2591. PubMed ID: 38073492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.